Land use and Zoning: No impact.
Community Facilities, Utilities, Police Services, Fire Protection, Health and Emergency Services: No impact.
Natural Hazards: No impact.

Rationale for Decision

In terms of programmatic feasibility, there are no meaningful environmental distinctions to be drawn among the three construction alternatives at the Rich's site and the leasing alternative choosing another location. Having considered all reasonably foreseeable major impacts to the environment, and determined practicable means to avoid or minimize environmental harm, while meeting the GSA objective of consolidating Federal agencies into a downtown location into Class "A" office space that will meet GSA and PBS standards, GSA has decided to lease a 1.4 million occupiable square foot building and a parking deck for 2200 vehicles from the City of Atlanta at the site of the former Rich's Department store for a period of 27 years.

Dated: August 2, 1993.
Paul L. Allison,
Acting Regional Administrator.
[FR Doc. 93–19315 Filed 8–11–93; 8:45 am]
BILLING CODE 6820–23–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Agency Forms Submitted to the Office of Management and Budget for Clearance

On Fridays, the Department of Health and Human Services, Office of the Secretary publishes a list of information collections it has submitted to the Office of Management and Budget (OMB) for clearance in compliance with the Paperwork Reduction Act (44 U.S.C. chapter 35). The following are those information collections recently submitted to OMB.

1. HHS Acquisition Regulation—HHSAR Part 332 Contract Financing—0990–0134—Extension—The requirements of HHSAR Part 332 are needed to ascertain costs associated with certain contracts so as to timely pay contractors. Respondents: State or local governments, small businesses or organizations. Burden Information for the Cost Sharing Clause—Number of Respondents: 24; Annual Number of Responses: 10; Average Annual Burden per Respondent: 1 hours; Estimated Burden: 240 hours—Burden Information for the Letter of Credit Clause—Number of Respondents: 268; Annual Number of Responses: 4; Average Annual Burden per Respondent: 1 hours; Estimated Burden: 1,172 hours—Total Burden: 1,412 hours.

2. HHS Acquisition Regulation—HHSAR Part 333 Disputes and Appeals—0990–0133—Extension—The Litigation and Claims Clause is needed to inform Government personnel of actions filed against Government contracts. Respondents: State or local governments, businesses or other for-profit institution, non-profit institutions, small businesses or organizations; Number of Respondents: 100; Annual Number of Responses: 1; Average Annual Burden per Respondent: .5 hours; Estimated Burden: 50 hours.

3. HHS Acquisition Regulation—HHSAR Part 324 Protection of Privacy and Freedom of Information—0990–0136—Extension—The Confidentiality of Information requirements are needed to prevent improper disclosure of confidential data. Respondents: State or local governments, businesses or other for-profit institution, non-profit institutions, small businesses or organizations; Number of Respondents: 449; Annual Number of Responses: 1; Average Annual Burden per Respondent: 8 hours; Estimated Burden: 3592 hours.

4. HHS Acquisition Regulation—HHSAR Part 316 Types of Contracts—0990–0138—Extension—The Negotiated Overhead Rate—Fixed clause is needed since fixed rates are authorized by OMB Circular and a clause is not provided in the Federal Acquisition Regulation (FAR). Respondents: non-profit institutions; Number of Respondents: 376; Annual Number of Responses: 1; Average Annual Burden per Respondent: 10 hours; Estimated Burden: 3,760 hours.

5. HHS Acquisition Regulation—HHSAR Part 342 Contract Administration—0990–0131—Extension—The requirement for Notification of Cost Overrun is necessary better administer HHS contracts. Respondents: State or local governments, businesses or other for-profit institution, non-profit institutions, small businesses or organizations; Number of Respondents: 14; Annual Number of Responses: 1; Average Annual Burden per Respondent: 20 hours; Estimated Burden: 900 hours.

OMB Desk Officer: Allison Eydt.

Copies of the information collection packages listed above can be obtained by calling the OS Reports Clearance Officer on (202) 619–0511. Written comments and recommendations for the proposed information collection should be sent directly to the OMB desk officer designated above at the following address: OMB Reports Management Branch, New Executive Office Building, room 3208, Washington, DC 20503.

Dated: July 30, 1993.
Dennis P. Williams,
Deputy Assistant Secretary, Budget.
[FR Doc. 93–19340 Filed 8–11–93; 8:45 am]
BILLING CODE 4150–04–M

Food and Drug Administration

[Docket No. 84N–0154]

Revised Draft of "Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals (1993);" Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration is announcing the availability of a revised draft of a points to consider (PTC) document entitled "Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals (1993)." The revised draft PTC document is concerned with the characterization of cell lines used to produce biological products which are subject to licensure under the U.S. Public Health Service Act and also with the identification of possible adventitious infectious agents from the cell lines which may contaminate the final product.

ADDRESSES: Submit written requests for single copies of the revised draft PTC document to the Congressional and Consumer Affairs Branch (HFM–12), Food and Drug Administration, 1401 Rockville Pike, suite 200N, Rockville, MD 20852–1448. Send two self-addressed adhesive labels to assist that office in processing your requests. Submit written comments on the revised draft PTC document to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857. Two copies of any comments are to be submitted, except that individuals may submit one. Requests and comments should be identified with the docket number found in brackets in the heading of this document. The revised draft PTC document and received comments are available for public examination in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

FOR FURTHER INFORMATION CONTACT: Stephen Ripley, Center for Biologics

Evaluation and Research (HFM–635), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–594–3074.

SUPPLEMENTARY INFORMATION: FDA is announcing the availability of a revised draft PTC document entitled "Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals (1993)". This document supersedes the "Points to Consider (PTC) in the Characterization of Cell Lines Used to Produce Biologicals (1987)" announced in the **Federal Register** of April 4, 1988 (53 FR 10948). The revised draft PTC reflects a number of recommendations emanating from several international workshops held since the issuance of the previous PTC. A number of tests previously recommended have been revised or eliminated.

The revised draft PTC provides information regarding the characterization of cell lines used to produce biological products which are subject to licensure under the U.S. Public Health Service Act and also with the identification of possible adventitious infectious agents from the cell lines which might contaminate the final product. FDA's regulation governing biological products contain requirements regarding final product uniformity, consistency from lot-to-lot and freedom from adventitious infectious agents. Topics addressed in the revised draft PTC document include: (1) History and general characteristics of the cell line; (2) the cell bank system; (3) production cultures and product testing; (4) quality control testing; and (5) validation of viral elimination.

Advances in biotechnology are occurring rapidly. Each new product should be evaluated in light of its own particular characteristics and the cell line and manufacturing process being used. Therefore, information in the revised draft PTC is subject to change as new and significant findings become available. Accordingly, discussion in the revised draft PTC should be interpreted as raising scientific issues that manufacturers who produce biological products from cell lines should consider, both during product development under investigational new drug applications (IND's) and before submitting product license applications (PLA's).

As with other PTC documents, FDA does not intend this draft PTC document to be all-inclusive. Alternative approaches may well be suitable in specific situations, and certain aspects may not be applicable to all situations. Furthermore, the scientific basis for determining the appropriateness of the points specified for consideration here is developing rapidly and more appropriate approaches may be developed in the future. Therefore, the Center for Biologics Evaluation and Research will review the adequacy of testing of any cell line on a case-by-case basis. This PTC document does not bind FDA and does not create or confer any rights, privileges, or benefits on or for any private person, but is intended merely for guidance.

Interested persons may submit written comments on the revised draft PTC document to the Dockets Management Branch (address above). Such comments received will be considered in determining whether further revision of the revised draft PTC document is warranted.

Dated: August 4, 1993.

Michael R. Taylor,

Deputy Commissioner for Policy.

[FR Doc. 93–19299 Filed 8–11–93; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 93F–0166]

M. & G. Ricerche S.p.A.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that M. & G. Ricerche S.p.A., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of pyromellitic dianhydride as a modifier in the manufacture of polyethylene terephthalate copolymers intended for food-contact applications.

DATES: Written comments on petitioner's environmental assessment by September 13, 1993.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Vir Anand, Center for Food Safety and Applied Nutrition (HFS–216), Food and Drug Administration, 200 C St. SW.,Washington, DC 20204, 202–254–9500.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 3B4375) has been filed by M. & G. Ricerche S.p.A., c/o Delta Analytical Corp., 7910 Woodmont Ave., suite 1000, Bethesda, MD 20814. The petition proposes that the food additive regulation, § 177.1630 *Polyethylene phthalate polymers* (21 CFR 177.1630), be amended to provide for the safe use of pyromellitic dianhydride as a modifier, at a level not to exceed 0.5 weight percent, in the manufacture of polyethylene terephthalate copolymers intended for food-contact applications.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before September 13, 1993, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the **Federal Register**. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: August 5, 1993.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 93–19303 Filed 8–11–93; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 93C–0248]

BASF Corp.; Filing of Color Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that BASF Corp., has filed a petition proposing that the color additive

regulations be amended to provide for the safe use of canthaxanthin as a color additive in the feed of salmonid fish.

DATES: Written comments on petitioner's environmental assessment by September 13, 1993.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: James C. Wallwork, Center for Food Safety and Applied Nutrition (HFS–217), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–254–9515.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 721), (21 U.S.C. 379e), notice is given that a color additive petition (CAP 3C0240) has been filed by BASF Corp., 100 Cherry Hill Rd., Parsippany, NJ 07054. The petition proposes to amend the color additive regulations to provide for the safe use of canthaxanthin as a color additive in the feed of salmonid fish.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before September 13, 1993, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the **Federal Register**. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: August 5, 1993.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 93–19368 Filed 8–11–93; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 93F–0247]

Exxon Chemical Company; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Exxon Chemical Co. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of ethylene/hexene-1 copolymers containing a maximum of 20 percent by weight of polymer units derived from hexene-1 as components of articles intended for use in contact with food.

DATES: Written comments on petitioner's environmental assessment by September 13, 1993.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Hortense S. Macon, Center for Food Safety and Applied Nutrition (HFS–216), Food and Drug Administration, 200 C St. SW., Washington, DC 20204,202–254–9500.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 3B4379) has been filed by Exxon Chemical Co., P.O. Box 1607, Baton Rouge, LA 70821–1607. The petition proposes that the food additive regulations in § 177.1520 *Olefin polymers* (21 CFR 177.1520) be amended to provide for the safe use of ethylene/hexene-1 copolymers containing a maximum of 20 percent by weight of polymer units derived from hexene-1 as components of articles intended for use in contact with food.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before September 13, 1993, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the **Federal Register**. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: August 5, 1993.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 93–19367 Filed 8–11–93; 8:45 am]

BILLING CODE 4160–01–F

International Workshop on Harmonisation of Reporting of Adverse Events Following Vaccination

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER) is announcing an international workshop entitled "International Workshop on Harmonisation of Reporting of Adverse Events Following Vaccination." The objective of this workshop is to encourage international harmonization of surveillance programs by communicating experiences, exchanging information, developing standards for reporting, information management, and monitoring. This workshop will help CBER in preparing guidance consistent with international programs.

DATES: The workshop will be held on Monday, September 27, 1993, and Tuesday, September 28, 1993, from 8 a.m. to 6 p.m., and Wednesday, September 29, 1993, from 8 a.m. to 12 m.

ADDRESSES: The workshop will be held at the Holiday Inn Bethesda, 8120 Wisconsin Ave., Bethesda, MD 20814.

FOR FURTHER INFORMATION CONTACT:

To receive a brochure containing information on the agenda, registration, hotel, and travel: Pamela S. Milan, KRA Corp., 1010 Wayne Ave., suite 950, Silver Spring, MD 20910, 301–495–1591; facsimile 301–495–2919.

Regarding this notice: Paula S. McKeever, Center for Biologics Evaluation and Research (HFM–635), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–594–3074.

SUPPLEMENTARY INFORMATION: The workshop entitled "International Workshop on Harmonisation of Reporting of Adverse Events Following Vaccination" is cosponsored by CBER; the National Vaccine Program Office; the National Institute of Allergy and Infectious Diseases; the Centers for Disease Control and Prevention; the Health Resources and Services Administration; and the World Health Organization. The purpose of the workshop is to encourage international harmonization of surveillance of adverse experience reporting programs for vaccines through an exchange of information. The objectives of the workshop are to foster the development of definitions and basic requirements for the use of adverse event terminology and to encourage the standardization of data specific fields for use in reporting and evaluating adverse event case reports. Various national vaccine reporting and surveillance systems will be presented at the workshop to promote the harmonization of international surveillance programs.

Speakers from representative national regulatory agencies, national disease prevention agencies, pharmaceutical manufacturers, and academia will address the following topics:

(1) The systems used by various national regulators, other public health agencies, and manufacturers to process and monitor vaccine adverse event reports;

(2) The development of definitions and basic requirements for the use of surveillance data bases and their use in evaluating case reports; and

(3) Discussions of how internationally standardized data specific fields can promote the worldwide dissemination of information via computerized data bases.

Dated: August 4, 1993.

Michael R. Taylor,

Deputy Commissioner for Policy.

[FR Doc. 93–19370 Filed 8–11–93; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 93F–0269]

Lonza, Inc.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Lonza, Inc., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of didecyldimethylammonium chloride as a preservative on wooden articles intended to contact food.

DATES: Written comments on the petitioner's environmental assessment by September 13, 1993.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Andrew J. Zajac, Center for Food Safety and Applied Nutrition (HFS–216), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–254–9500.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 3B4387) has been filed on behalf of Lonza, Inc., c/o Delta Analytical Corp., 7910 Woodmont Ave., Suite 1000, Bethesda, MD 20814. The petition proposes that the food additive regulations in § 178.3800 *Preservatives for wood* (21 CFR 178.3800) be amended to provide for the safe use of didecyldimethylammonium chloride as a preservative on wooden articles intended to contact food.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before September 13, 1993, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the **Federal Register**. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 25.40(c).

Dated: August 5, 1993.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 93–19369 Filed 8–11–93; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 93F–0244]

National Starch and Chemical Company; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that National Starch and Chemical Co., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of starch, modified by treatment with diethylaminoethylchloride, hydrochloride salt and 2-chloro-*N*-(2, 2-dimethoxyethyl)-*N*-methylacetamide, as an internal sizing for paper and paperboard intended for use in contact with food.

DATES: Written comments on petitioner's environmental assessment by September 13, 1993.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm 1–23, 12420 Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Mitchell Cheeseman, Center for Food Safety and Applied Nutrition (HFS–216), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–254–9511.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 3B4385) has been filed by National Starch and Chemical Co., Finderne Ave., Bridgewater, NJ 08807. The petition proposes to amend the food additive regulations in § 178.3520

Industrial starch-modified (21 CFR 178.3520) to provide for the safe use of starch, modified by treatment with diethylaminoethylchloride, hydrochloride salt (CAS Reg. No. 869–24–9) and 2-chloro-*N*-(2,2-dimethoxyethyl)-*N*-methylacetamide (CAS Reg. No. 69184–36–7), as an internal sizing for paper and paperboard intended for use in contact with food.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4 (b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before September 13, 1993, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the **Federal Register**. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: August 5, 1993.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 93–19371 Filed 8–11–93; 8:45 am]

BILLING CODE 4160–01–F

National Institutes of Health

Meeting of the National Advisory Council for Human Genome Research

Pursuant to Public Law 94–463, notice is hereby given of the meeting of the National Advisory Council for Human Genome Research, National Center for Human Genome Research, September 20 and 21, 1993, at the Holiday Inn Crowne Plaza, 1750 Rockville Pike, Rockville, Maryland.

This meeting will be open to the public on September 20, 1993, from 8:30 a.m. to 11:30 a.m. to discuss administrative details or other issues relating to committee activities. Attendance by the public will be limited to space available.

In accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5, U.S.C. and section 10(d) of Public Law 94–463, the meeting will be closed to the public on September 20 at 11:30 a.m. to recess and on September 21, 1993, from 8:30 a.m. to adjournment, for the review, discussion and evaluation of individual grant applications. The applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Dr. Elke Jordan, Deputy Director, National Center for Human Genome Research, National Institutes of Health, Building 38A, room 605, Bethesda, Maryland 20892 (301) 496–0844, will furnish the meeting agenda, rosters of Committee members and consultants, and substantive program information upon request. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ms. Jane Ades, (301) 402–2205, two weeks in advance of the meeting.

(Catalogue of Federal Domestic Assistance Program No. 93.172, Human Genome Research.)

Dated: August 5, 1993.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 93–19359 Filed 8–11–93; 8:45 am]

BILLING CODE 4140–01–M

National Institute of Environmental Health Sciences; Meeting of National Advisory Environmental Health Sciences Council

Pursuant to Public Law 92–463, notice is hereby given of the meeting of the National Advisory Environmental Health Sciences Council, September 13–14, 1993, at the National Institute of Environmental Health Sciences, Building 101 Conference Room, South Campus, Research Triangle Park, North Carolina.

This meeting will be open to the public on September 13 from 9 a.m. to approximately 5 p.m. for the report of the Director, NIEHS, and for discussion of the NIEHS budget, program policies and issues, recent legislation, and other items of interest. Attendance by the public will be limited to space available.

In accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5, U.S.C. and section 10(d) of Public Law 92–463, the meeting will be closed to the public on September 14, from 8:30 a.m. to adjournment, for the review, discussion and evaluation of individual grant applications. These applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Winona Herrell, Committee Management Officer, NIEHS, Bldg. 31, room B1C02, NIH, Bethesda, Md. 20892 (301) 496–3511, will provide summaries of the meeting and rosters of council members. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ms. Herrell in advance of the meeting.

Dr. Anne Sassaman, Director, Division of Extramural Research and Training, NIEHS, P.O. Box 12233, Research Triangle Park, North Carolina 27709, (919) 541–7723, FTS 629–7723, will furnish substantive program information.

(Catalog of Federal Domestic Assistance Program Nos. 93.113, Biological Response to Environmental Agents; 93.114, Applied Toxicological Research and Testing; 93.115, Biometry and Risk Estimation; 93.894, Resource and Manpower Development, National Institutes of Health)

Dated: August 5, 1993.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 93–19360 Filed 8–11–93; 8:45 am]

BILLING CODE 4140–10–M

National Institute on Aging; Meeting of the National Advisory Council on Aging

Pursuant to Public Law 92–463, notice is hereby given of the meeting of the National Advisory Council on Aging, National Institute on Aging, September 29–30, 1993, to be held at the National Institutes of Health, Building 31, Conference Room 10, Bethesda, Maryland. This meeting will be open to the public on Wednesday, September 29, from 8 a.m. to 12 noon for a status report by the Director, NIA, a report on the Biology of Aging Program, and a report on the Working Group on Program.